Topas Therapeutics Appoints Rupert Sandbrink, M.D., Ph.D., as Chief Development Officer and Chief Medical Officer
In All, PortfolioHighly accomplished pharmaceutical executive with many years of clinical development, medical affairs, and regulatory experience at Bayer and Schering To lead Topas’ clinical development and regulatory affairs Hamburg, 26 October 2017, – Topas Therapeutics GmbH (Topas), a Hamburg, Germany-based private platform company leveraging the natural…